Rachael Morton
Dr. Rachael Morton is a research fellow in the School of Public Health, Sydney Medical School at the University of Sydney, Australia. She has post-graduate qualifications in clinical epidemiology, and health economics and was the clinical trials manager for the Melanoma Institute Australia (formerly Sydney Melanoma Unit) from 2004-2007. Rachael is an executive member of the Australia and New Zealand Melanoma Trials Group (ANZMTG) and board member of the Melanoma Network. She has published on the role of sentinel node biopsy in melanoma treatment, the reproducibility of lymphoscintigraphy, and the value of diagnostic imaging in melanoma follow-up. She is a chief investigator for a randomized controlled trial into high dose vitamin D for patients at risk of melanoma recurrence, and associate investigator for a trial of whole brain radiotherapy following surgical resection of melanoma brain metastases. Rachael’s current melanoma research includes the evaluation of post treatment follow-up of stage I/II cutaneous melanoma from the perspective of clinicians and patients.